LAB vs TPR · rev $174.4M vs P/E 46, rev $8.00B
Standard Biotools Inc (LAB) versus Tapestry Inc (TPR) — a side-by-side from cached financials, not a winner call.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
Tapestry Inc (TPR) is a luxury goods company listed on NYSE.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
Latest reported TPR revenue for 2026-06-27 was $8.00B. Net income was $1.53B. Revenue was up 14.2% from 2025-06-28 to 2026-06-27. TPR currently screens at market cap $30.81B and trailing P/E 46.3.
LAB currently screens at market cap $317.1M. TPR currently screens at market cap $30.81B and trailing P/E 46.3.
Not investment advice. Open the LAB and TPR stock pages for the full models.
Not investment advice.